MAPT and Alzheimer disease: Similarly with a 95% NPV for Advanced stage AD when applied across all CI participants, plasma p217+tau may be used to screen out persons unlikely to have Advanced AD, with tau PET then required to separate Advanced AD from lower stages in those above the plasma p217+tau threshold.